Taliglucerase alfa — Complete Research Guide (2026)

Last updated 2026-06-30

What is Taliglucerase alfa?

Taliglucerase alfa (brand name Elelyso) is a recombinant human glucocerebrosidase (beta-glucosidase) and was the first therapeutic protein produced in genetically engineered plant (carrot) cells to reach the market. It is an FDA-approved enzyme replacement therapy, granted approval in May 2012 for type 1 (non-neuronopathic) Gaucher disease in adults, with a later pediatric indication.

It is a prescription biologic given by intravenous infusion, not a supplement or research chemical.

Its evidence base includes a pivotal phase 3 randomized trial in treatment-naive patients plus switchover, pediatric, and multi-year extension studies.

How does Taliglucerase alfa work?

Type 1 Gaucher disease results from deficient lysosomal glucocerebrosidase, causing glucocerebroside (glucosylceramide) to accumulate in macrophages of the spleen, liver, and bone marrow.

Taliglucerase alfa replaces the missing enzyme, allowing lysosomal breakdown of the accumulated substrate.

What does the research say about Taliglucerase alfa?

• In the pivotal phase 3 trial, taliglucerase alfa reduced enlarged spleen and liver volume and improved hemoglobin and platelet counts in treatment-naive type 1 Gaucher disease. ^[1]
• Patients switched from imiglucerase maintained stable organ volumes and blood counts on taliglucerase alfa in a phase 3 switchover study. ^[2]
• Clinical benefits were sustained over five years of treatment in treatment-naive adults. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

• [1] Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease — Zimran A et al., Blood 2011. (Phase 3 randomized controlled trial)
• [2] A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase — Pastores GM et al., Blood Cells, Molecules and Diseases 2014. (Phase 3 open-label switchover trial)
• [3] Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease — van Dussen L et al., Blood Cells, Molecules and Diseases 2013. (Clinical study (imaging endpoint))
• [4] Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naive patients with Gaucher disease — Zimran A et al., Blood Cells, Molecules and Diseases 2019. (Long-term extension study)
• [5] Management of Gaucher disease: enzyme replacement therapy — Zimran A et al., Pediatric Endocrinology Reviews 2014. (Review)

Dosing context

In clinical practice it is given by a healthcare professional as an intravenous infusion, typically once every two weeks, with the dose based on body weight.

This is context only, not a recommendation; the regimen and monitoring are set by the treating specialist under the approved label.

Side effects & safety profile

The most frequently reported adverse events are infusion-related (hypersensitivity-type) reactions such as headache, itching, flushing, and fatigue, which are usually mild to moderate and manageable with rate adjustment or premedication.

Serious hypersensitivity reactions can occur, so infusions are administered under supervision.

As with other enzyme replacement therapies, some patients develop anti-drug antibodies; type 1 Gaucher disease is the non-neuronopathic form, and this intravenous enzyme is not expected to address any central nervous system involvement seen in other Gaucher subtypes.

Stacking & combinations

It is a disease-specific enzyme replacement therapy used on its own and is not meant to be combined or stacked with other peptides or performance compounds.

Finding Taliglucerase alfa vendors

User reviews

Frequently asked questions

References

1. [1] Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease — Zimran A et al., Blood 2011. PMID: 21900191. View sourceStudy: Phase 3 randomized controlled trialTaliglucerase alfa reduced spleen and liver volume and improved hematologic parameters in treatment-naive type 1 Gaucher disease.
2. [2] A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase — Pastores GM et al., Blood Cells, Molecules and Diseases 2014. PMID: 24950666. View sourceStudy: Phase 3 open-label switchover trialPatients switched from imiglucerase remained clinically stable on taliglucerase alfa.
3. [3] Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease — van Dussen L et al., Blood Cells, Molecules and Diseases 2013. PMID: 23199589. View sourceStudy: Clinical study (imaging endpoint)Treatment was associated with favorable bone marrow (fat-fraction) responses in type 1 Gaucher disease.
4. [4] Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naive patients with Gaucher disease — Zimran A et al., Blood Cells, Molecules and Diseases 2019. PMID: 27499018. View sourceStudy: Long-term extension studyOrgan-volume and hematologic benefits were sustained over five years with an acceptable safety profile.
5. [5] Management of Gaucher disease: enzyme replacement therapy — Zimran A et al., Pediatric Endocrinology Reviews 2014. PMID: 25345089. View sourceStudy: ReviewReviews enzyme replacement therapies for Gaucher disease, including taliglucerase alfa, in clinical management.